Search Results | Blood | American Society of Hematology

1-20 of 302

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Redefining nonmeasurable multiple myeloma using mass spectrometry

Hannah V. Giles, Mark A. Cook, Mark Trehane Drayson, Gordon Cook, Nicola Jane Wright, Simon John North, Stephen Harding, David A. Cairns, Anna Hockaday, Martin F. Kaiser, Paul Moss, Faith E. Davies, Gareth J. Morgan, Graham Jackson, Guy Pratt

Blood (2022) 139 (6): 946–950.

DOI: https://doi.org/10.1182/blood.2021013794

Published: 2022

Includes: Supplemental data

Journal Articles

N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma

Shiqiao Ye, Yu Chen, Bo Hu, Huayu Huang, Yuxiao Sun, James P Stewart, Sarah K Johnson, Bart Barlogie, Maurizio Zangari, Guido Tricot, Faith E Davies, Gareth J Morgan, Brian A Walker, Fenghuang Zhan, Frits van Rhee, John D Shaughnessy, Jr., Ya-Wei Qiang

Blood (2021) 138 (Supplement 1): 1572.

DOI: https://doi.org/10.1182/blood-2021-148624

Published: 2021

Journal Articles

Unifying the Definition of High-Risk in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2714.

DOI: https://doi.org/10.1182/blood-2021-148502

Published: 2021

Journal Articles

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Ahmad-Samer Al-Homsi, Sebastien Anguille, Dries Deeren, Taiga Nishihori, Nathalie Meuleman, Maher Abdul-Hay, Gareth J. Morgan, Jason Brayer, Nathalie Braun, Caroline Lonez, Marie-Sophie Dheur, Erik Alcantar-Orozco, David Gilham, Anne Flament, Frédéric F. Lehmann

Blood (2021) 138 (Supplement 1): 2817.

DOI: https://doi.org/10.1182/blood-2021-147738

Published: 2021

Journal Articles

Multistate Models Demonstrate That Lenalidomide Maintenance Enhances Survival By Prolonging Time in First Remission for Patients Treated in the UK NCRI Myeloma XI Randomised Trial

Zoe Craig, Christopher Parrish, Charlotte Pawlyn, Martin F. Kaiser, Catherine Olivier, John R Jones, Mark T Drayson, Roger G Owen, Matthew W Jenner, Gordon Cook, Walter Martin Gregory, Faith E Davies, Gareth J. Morgan, Graham Jackson, David Cairns

Blood (2021) 138 (Supplement 1): 3758.

DOI: https://doi.org/10.1182/blood-2021-150631

Published: 2021

Journal Articles

Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes

Blood (2021) 138 (Supplement 1): 723.

DOI: https://doi.org/10.1182/blood-2021-150767

Published: 2021

Journal Articles

Deep Profiling of the Immune Microenvironment throughout Myeloma Disease Stages

Megan Darrington, Frits van Rhee, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Fenghuang Zhan, Brian A Walker, Gareth J. Morgan, Sarah K Johnson

Blood (2021) 138 (Supplement 1): 727.

DOI: https://doi.org/10.1182/blood-2021-148590

Published: 2021

Journal Articles

A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2676.

DOI: https://doi.org/10.1182/blood-2021-148692

Published: 2021

Journal Articles

The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse

John R Jones, Charlotte Pawlyn, Niels Weinhold, Timothy Cody Ashby, Brian A Walker, Christopher P. Wardell, David Cairns, Walter Martin Gregory, Martin F. Kaiser, Gordon Cook, Mark T Drayson, Roger G Owen, Graham Jackson, Faith E Davies, Gareth J. Morgan

Blood (2021) 138 (Supplement 1): 2683.

DOI: https://doi.org/10.1182/blood-2021-152123

Published: 2021

Journal Articles

Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients

Charlotte Pawlyn, Faith E Davies, Tom Menzies, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Roger G Owen, Mark T Drayson, David Cairns, Gareth J. Morgan, Graham Jackson

Blood (2021) 138 (Supplement 1): 2907.

DOI: https://doi.org/10.1182/blood-2021-151102

Published: 2021

Journal Articles

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Blood (2021) 138 (Supplement 1): 3271.

DOI: https://doi.org/10.1182/blood-2021-145927

Published: 2021

Journal Articles

Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd)

Blood (2021) 138 (Supplement 1): 325.

DOI: https://doi.org/10.1182/blood-2021-149112

Published: 2021

Journal Articles

Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpassstudy

Louis Williams, Patrick Blaney, Eileen M Boyle, Hussein Ghamlouch, Yubao Wang, Jinyoung Choi, Michael A Bauer, Ariel Siegel, James Stoeckle, Beatrice Razzo, Daniel Auclair, David Kaminetzky, Marc Braunstein, Benedetto Bruno, Arnaldo A. Arbini, Brian A Walker, Faith E. Davies, Gareth J Morgan

Blood (2021) 138 (Supplement 1): 4117.

DOI: https://doi.org/10.1182/blood-2021-148854

Published: 2021

Journal Articles

Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years

Rakesh Popat, Zoe Craig, Faith E Davies, David Cairns, Catherine Olivier, J Anthony Child, Gareth J. Morgan, Gordon Cook, Graham H Jackson

Blood (2021) 138 (Supplement 1): 4118.

DOI: https://doi.org/10.1182/blood-2021-149148

Published: 2021

Journal Articles

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Hannah Victoria Giles, Mark T Drayson, Nicola Wright, Gordon Cook, Faith E. Davies, Gareth J Morgan, Ruth M. de Tute, Roger G Owen, David Cairns, Anna Hockaday, Tom Menzies, Martin F. Kaiser, Charlotte Pawlyn, Graham Jackson, Guy Pratt

Blood (2021) 138 (Supplement 1): 820.

DOI: https://doi.org/10.1182/blood-2021-150479

Published: 2021

Journal Articles

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

Meletios A. Dimopoulos, S. Vincent Rajkumar, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, Maria-Victoria Mateos, Gareth J. Morgan, Arun Kumar, Kaveri Suryanarayan, Alexander Vorog, Andrew Fergus, Richard Labotka

Blood (2021) 138 (Supplement 1): 1656.

DOI: https://doi.org/10.1182/blood-2021-150476

Published: 2021

Journal Articles

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Wee-Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji Kumar, Philip Twumasi-Ankrah, Arun Kumar, Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios A. Dimopoulos, S. Vincent Rajkumar

Blood (2021) 138 (Supplement 1): 1678.

DOI: https://doi.org/10.1182/blood-2021-147838

Published: 2021

Journal Articles

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

Charlotte A. Bradbury, Zoe Craig, Gordon Cook, Charlotte Pawlyn, David A. Cairns, Anna Hockaday, Andrea Paterson, Matthew W. Jenner, John R. Jones, Mark T. Drayson, Roger G. Owen, Martin F. Kaiser, Walter M. Gregory, Faith E. Davies, J. Anthony Child, Gareth J. Morgan, Graham H. Jackson

Blood (2020) 136 (9): 1091–1104.

DOI: https://doi.org/10.1182/blood.2020005125

Published: 2020

Includes: Supplemental data

Journal Articles

The genomic landscape of plasma cells in systemic light chain amyloidosis

Blood (2018) 132 (26): 2775–2777.

DOI: https://doi.org/10.1182/blood-2018-08-872226

Published: 2018

Includes: Supplemental data

Journal Articles

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Blood (2018) 132 (23): 2465–2469.

DOI: https://doi.org/10.1182/blood-2018-06-857250

Published: 2018

Includes: Supplemental data

2 3 4 5

NARROW

Redefining nonmeasurable multiple myeloma using mass spectrometry

N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma

Unifying the Definition of High-Risk in Multiple Myeloma

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Multistate Models Demonstrate That Lenalidomide Maintenance Enhances Survival By Prolonging Time in First Remission for Patients Treated in the UK NCRI Myeloma XI Randomised Trial

Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes

Deep Profiling of the Immune Microenvironment throughout Myeloma Disease Stages

A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma

The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse

Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd)

Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpassstudy

Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

The genomic landscape of plasma cells in systemic light chain amyloidosis

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only